BNC 1601
Alternative Names: BNC-1601Latest Information Update: 28 Sep 2024
At a glance
- Originator BONAC Corporation
- Class Eye disorder therapies; Nucleic acids
- Mechanism of Action Cell surface receptor modulators; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Age-related macular degeneration
- No development reported Diabetic retinopathy; Uveitis
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Diabetic-retinopathy in Japan (Parenteral)
- 28 Sep 2024 No recent reports of development identified for preclinical development in Uveitis in Japan (Parenteral)
- 01 Sep 2022 Preclinical trials in Age-related macular degeneration in Japan (unspecified route) before August 2022 (BONAC Corporation pipeline, August 2022)